LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mindray Launches BC-700 Series Integrated CBC and ESR Hematology Analyzer for Small-to-Mid Sized Labs

By LabMedica International staff writers
Posted on 17 Mar 2022
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)
Image: BC-700 Series Integrated CBC and ESR Hematology Analyzer (Photo courtesy of Mindray)

Traditionally, erythrocyte sedimentation rate (ESR) tests, which measure how quickly red blood cells (RBCs) settle in diluted plasma over a specified period of time, are performed on an independent analyzer, and can take up to 60 minutes to get the results. However, there is a need for integrated testing for CBC and ESR. Now, the first all-in-one hematology solution that combines 5-part differential with ESR analysis yields both CBC and ESR results with just one test in merely 1.5 minutes, significantly improving workflow and testing efficiency while benefiting patients with quicker blood test reports.

Mindray (Shenzhen, China) has launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. The BC-700 Series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.

Striving to benefit more laboratories worldwide, the BC-700 Series adopts Mindray’s core hematology technology of SF Cube 3D analysis and is built from the same platform as its high-end BC-6000 Series, but in a smaller footprint. In SF Cube technology, target cells are subject to a 3D analysis using bi-angular laser scatter signals and fluorescence. The 3D scattergrams generated with the cellular information can help clinical experts to identify and differentiate cell populations, in particular abnormal clusters, providing a more reliable result to the doctor.

Powered by the SF Cube analysis technology, Mindray has developed many useful hematology parameters. With the new parameter, PLT-H, the BC-700 Series can more easily address the challenges that were previously inadequately met by conventional hematology analyzers, providing an accurate optical platelet count result in every CBC and DIFF test. By using patented reagents with cutting-edge technology, the BC-700 Series also allows the platelet clumps to be de-aggregated, offering laboratories a complete solution for reliable platelet analysis.

"We designed and built this analyzer series, because Mindray believes all labs matter. Every laboratory needs solutions that empower trust and accurate results, and this is what drives us to develop technologies and innovations that go above and beyond your requirements," said Shane Wan, Director of International IVD Product Line, Mindray.

Related Links:
Mindray 

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more